Retreatment with venetoclax and rituximab in CLL patients achieved 100% response rates and prolonged progression-free ...
Ianalumab targets the BAFF receptor, depleting malignant B cells and enhancing ibrutinib's efficacy, offering a potential ...
June 11, 2009 (Berlin, Germany) — The novel CD20 monoclonal antibody ofatumumab (Arzerra) has demonstrated superior response rates in 2 challenging groups of chronic lymphocytic leukemia (CLL) ...
In November 2025, Nurix appointed accomplished biopharmaceutical leader Roger Dansey, M.D., to its Board of Directors, adding ...
For patients who have chronic lymphocytic leukemia (CLL), experiencing Richter transformation with central nervous system ...
Nurix Therapeutics (NRIX) stock: bexobrutideg’s BTK degradation shows strong efficacy in B-cell cancers, backed by $650M cash & 2026 catalysts—read now.
The risk reduction observed in BRUIN CLL-313 is among the most compelling observed for a single agent BTK inhibitor in a front-line CLL study These data will be simultaneously published in the Journal ...
Four trials presented at the recent American Society of Clinical Oncology (ASCO) meeting showed promise of new drug combinations or monotherapies in treating chronic lymphocytic leukemia (CLL) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results